Thus, our findings pertaining to limited foam cell formation by augmentation of lipid efflux provide an additional–perhaps more direct–mechanism in the atheroprotective role of inhibiting systemic BMP signaling

Thus, our findings pertaining to limited foam cell formation by augmentation of lipid efflux provide an additional–perhaps more direct–mechanism in the atheroprotective role of inhibiting systemic BMP signaling. Despite the promising results shown here, it is important to note that before human therapy could be considered using this approach, significantly longer and HMGIC more comprehensive toxicity studies would need to be performed to specifically define potential effects of short and long Bavisant dihydrochloride hydrate term treatment given its potential effects on iron related toxicities and tissue repair10,27,28. in plaques and peritoneal macrophages. Long-term LDN administration to Apo E (-/-) mice increased ABCA1 immunoreactivity within intraplaque macrophages by 3.7-fold (n=8; p=0.03), reduced oil-red-o positive lipid area by 50% (n=8; p=0.02) Bavisant dihydrochloride hydrate and decreased total plaque area by 43% (n=8; p=0.001). LDN suppressed liver hepcidin transcription and increased macrophage FPN, lowering intracellular iron and hydrogen peroxide production. LDN treatment increased macrophage ABCA1 and ABCG1 expression, significantly raised cholesterol efflux to ApoA-1 and decreased foam cell formation. All preceding LDN-induced effects on cholesterol efflux were reversed by exogenous hepcidin administration, suggesting that modulation of intracellular iron levels within macrophages as the mechanism by which LDN triggers these effects. == Conclusion == These data suggest that pharmacologic manipulation of iron homeostasis may be a promising target to increase macrophage reverse cholesterol transport and limit atherosclerosis. Keywords:iron, foam cell, macrophage, cholesterol efflux, atherosclerosis Atherosclerosis progresses through intracellular lipid accumulation within macrophages Bavisant dihydrochloride hydrate leading to foam cell formation and necrotic core growth1,2. Although current clinical strategies have focused on cholesterol lowering as a way to decrease lipid retention in the arterial wall, increasing macrophage lipid efflux has been suggested to be another promising strategy to limit foam cell formation and atherosclerosis3. Efflux of intracellular lipid occurs primarily through ATP-binding cassette (ABC) transporters, ABCA1 and ABCG1, resulting in removal of lipid from macrophages and reverse cholesterol transport to the liver through plasma high-density lipoproteins4-6. Genetic deletion of ABCA1 and ABCG1 augments foam cell formation Bavisant dihydrochloride hydrate while overexpression of these genes in macrophages slows progression of atherosclerotic lesions in animal models4,7. While elegant genetic studies lend important insights into disease mechanisms, their potential for clinical translation is limited since selective gene manipulation within humans is not currently a viable option. To utilize the therapeutic potential of increasing macrophage cholesterol efflux for the prevention of atherosclerosis in humans, new pharmacologic means to increase macrophage expression of lipid efflux transporters are needed. We recently described within areas of intraplaque hemorrhage in post mortem human atherosclerotic plaques a specific subtype of macrophages which we termed M(Hb). These macrophages resist foam cell formation bothin vivoand in response to exogenous cholesterol loading, have increased expression of ABCA1 and ABCG1, and anti-oxidative characteristics. We showed that the anti-oxidative properties of M(Hb) are causal in increased expression of ABCA1 and ABCG1 and originate from a reduction in intracellular free iron available for electron donation for reactive oxygen species (ROS) formation8. M(Hb) have reduced intracellular free iron due to increased expression of a free iron exporter, ferroportin (FPN). Our data suggest that reducing intracellular free iron levels within macrophages by increasing expression of macrophage FPN may be a promising strategy to increase expression of cholesterol efflux transporters. FPN is the only known mammalian free iron exporter expressed by macrophages and it is systemically degraded through ubiquitination after binding to a hepatic hormone, hepcidin9. The promoter elements of hepcidin are activated by SMAD 1/5/8 transcription factors, which are in turn activated through bone morphogenetic protein (BMP) signaling10. We used a novel small molecule inhibitor of BMP signaling, LDN 193189, which prevents the activation of SMAD 1/5/8 to suppress hepatic hepcidin production and increase expression of FPN within macrophages11. We explored the effects of this strategy on mouse atherosclerosis, macrophage intracellular iron levels, oxidative stress, lipid efflux, and foam cell formation. Our findings reveal that suppressing hepcidin by inhibiting BMP signaling through LDN 193189 (LDN) significantly increases expression of ABCA1 and ABCG1 and lipid efflux by macrophages, which is associated with reduced foam cell formation and atherosclerosis in the Apo E (-/-) mouse model. == Methods == == Chemicals == LDN-193189 (4-[6-(4-piperazin-1-ylphenyl)pyrazolo[1,5-a]pyrimidin-3-yl]quinoline) was.